|
|
Post by lakers on Jan 27, 2016 12:01:10 GMT -5
www.latimes.com/business/la-fi-mannkind-sale-report-20160126-story.htmlNews that MannKind is working with investment bankers on strategic options — including a possible sale — was reported Tuesday by Reuters, citing unnamed sources. “I can't comment on anything like that,” said Matt Pfeffer, MannKind's chief executive and chief financial officer. “The attorneys are quite emphatic about it.” In an interview with The Times this week, Pfeffer said MannKind is looking for new sales and distribution partners, rethinking the marketing strategy for Afrezza, working to get the drug approved for sale in markets outside of the United States, continuing to develop other inhalable drugs and licensing its technology to other drug developers. Lloyd Greif, chief executive of downtown L.A. investment bank Greif & Co., said all the activity that Pfeffer mentioned suggests the company is scrambling to stay afloat — and that it is likely considering any option, including a sale, that would stave off bankruptcy. “It conveys a sense of urgency. No question the company's back is up against the wall and they're going to look at any and all reasonable options,” Greif said. Ahmed Enany, chief executive of trade group Southern California Biomedical Council, said any company in MannKind's situation would consider a transaction. He also noted that choosing its finance chief to lead the company “made sense.” “Putting him at the helm might help the company explore options, including a sale,” Enany said.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2016 13:31:30 GMT -5
www.latimes.com/business/la-fi-mannkind-sale-report-20160126-story.htmlNews that MannKind is working with investment bankers on strategic options — including a possible sale — was reported Tuesday by Reuters, citing unnamed sources. “I can't comment on anything like that,” said Matt Pfeffer, MannKind's chief executive and chief financial officer. “The attorneys are quite emphatic about it.”In an interview with The Times this week, Pfeffer said MannKind is looking for new sales and distribution partners, rethinking the marketing strategy for Afrezza, working to get the drug approved for sale in markets outside of the United States, continuing to develop other inhalable drugs and licensing its technology to other drug developers. Lloyd Greif, chief executive of downtown L.A. investment bank Greif & Co., said all the activity that Pfeffer mentioned suggests the company is scrambling to stay afloat — and that it is likely considering any option, including a sale, that would stave off bankruptcy.
“It conveys a sense of urgency. No question the company's back is up against the wall and they're going to look at any and all reasonable options,” Greif said.
Ahmed Enany, chief executive of trade group Southern California Biomedical Council, said any company in MannKind's situation would consider a transaction. He also noted that choosing its finance chief to lead the company “made sense.”
“Putting him at the helm might help the company explore options, including a sale,” Enany said. LOL- Matt is really good at playing games. They should have let him off the leash a long time ago. You gotta wonder if AL has been his own worst enemy the past 12 months These comments make me nervous |
|
|
|
Post by dictatorsaurus on Jan 27, 2016 13:59:36 GMT -5
Of course they just had to add "struggling" in there  It seems to be ad advantage point for the hedgies or potential buyers to portray MNKD as weak as possible. Devalue before pulling the trigger for a buyout. |
|
|
|
Post by dreamboatcruise on Jan 27, 2016 14:02:21 GMT -5
LOL- Matt is really good at playing games. They should have let him off the leash a long time ago. You gotta wonder if AL has been his own worst enemy the past 12 months
These comments make me nervousLikely because they are echoing what we really already knew. |
|
|
|
Post by BlueCat on Jan 27, 2016 14:20:49 GMT -5
www.latimes.com/business/la-fi-mannkind-sale-report-20160126-story.htmlNews that MannKind is working with investment bankers on strategic options — including a possible sale — was reported Tuesday by Reuters, citing unnamed sources. “I can't comment on anything like that,” said Matt Pfeffer, MannKind's chief executive and chief financial officer. “The attorneys are quite emphatic about it.”In an interview with The Times this week, Pfeffer said MannKind is looking for new sales and distribution partners, rethinking the marketing strategy for Afrezza, working to get the drug approved for sale in markets outside of the United States, continuing to develop other inhalable drugs and licensing its technology to other drug developers. Lloyd Greif, chief executive of downtown L.A. investment bank Greif & Co., said all the activity that Pfeffer mentioned suggests the company is scrambling to stay afloat — and that it is likely considering any option, including a sale, that would stave off bankruptcy.
“It conveys a sense of urgency. No question the company's back is up against the wall and they're going to look at any and all reasonable options,” Greif said.
Ahmed Enany, chief executive of trade group Southern California Biomedical Council, said any company in MannKind's situation would consider a transaction. He also noted that choosing its finance chief to lead the company “made sense.”
“Putting him at the helm might help the company explore options, including a sale,” Enany said. LOL- Matt is really good at playing games. They should have let him off the leash a long time ago. You gotta wonder if AL has been his own worst enemy the past 12 months These comments make me nervous Actually, I find it reassuring. With all these class actions popping up, I'm sure he's been very well coached - especially as those suits are likely intended to cause the opposite of what Matt intends. Net - those that want low share price will benefit from maximum FUD = silence from the company. Lawyers circling increases gag response. So Matt's gotta walk this one carefully. Clearly, he understands that the definition of insanity is doing the same thing and expecting different results. He's changing the communication cadence - as far as he can. |
|
|
|
Post by nemzter on Jan 27, 2016 14:39:29 GMT -5
Matt better pray for a 'reasonable' solution before the Shareholders meeting in May - I'm sure it is going to be an interesting event to say the least.
|
|
